Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Transformed by the body

7-OH-CBD7-hydroxycannabidiol

The active metabolite of cannabidiol, formed by the liver, absent from the plant.

Unscheduled
Level of detail

C₂₁H₃₀O₃

CAS 50725-17-2

Family
Metabolite
Molar mass
330.47 g/mol

Updated on

In plain terms

7-OH-CBD is not a molecule of the plant: it is what the liver makes from cannabidiol once it has been swallowed. According to the regulatory data for the cannabidiol medicine, it remains active in animal seizure models, unlike the product that follows it. It circulates in the blood in a smaller amount than cannabidiol itself.

Receptors and activity

Target network

  • Blocks or inhibits

The lower the cited value, the closer the target sits to 7-OH-CBD: one ring per factor of 100. A target with no measured value stays on the edge.

Cited values

  1. CYP2A6InhibitorIC50 = 450 nM · human39 out of 100

    Nasrin et al. 2023, Chem Res Toxicol (new tab) · cotinine formation, microsomes from HEK293 overexpressing CYP2A6; binding-corrected IC50 (IC50,u); similar values in human liver microsomes

  2. CYP2B6InhibitorIC50 = 110 nM · human49 out of 100

    Nasrin et al. 2023, Chem Res Toxicol (new tab) · nornicotine formation, microsomes from HEK293 overexpressing CYP2B6; IC50,u (1.2 µM for cotinine formation)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of 7-OH-CBD, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

7-Hydroxycannabidiol is the main active metabolite of cannabidiol. It is formed by hydroxylation of carbon 7 by hepatic CYP2C19 and CYP2C9 (Beers 2021), then oxidised to 7-COOH-CBD via an aldehyde, 7-formyl-CBD (Wu 2025). According to the FDA labelling of Epidiolex, 7-OH-CBD is active in preclinical seizure models and 7-COOH-CBD is not; after repeated dosing, the area under the curve of 7-OH-CBD is 38 % lower than that of cannabidiol, that of 7-COOH-CBD about 40 times higher. In 12 healthy volunteers receiving 750 mg of cannabidiol twice daily, its mean Cmax was 81 ng/mL, for a metabolite-to-parent ratio of 0.25 (Zhang 2024). In vitro, it inhibits CYP2A6 and CYP2B6, enzymes of nicotine metabolism, at sub-micromolar unbound concentrations (Nasrin 2023). Its pharmacology at the cannabinoid receptors has only been addressed by molecular docking, and no trial has given this metabolite alone to humans.

Key sources.

History

Source
7-OH-CBD has not been described in the cannabis plant: it is a mammalian metabolite, formed in the liver after cannabidiol intake. Outside the body, it exists only as an analytical standard and research product.

Metabolic pathway

No plant pathway: 7-OH-CBD arises from hydroxylation of carbon 7 of cannabidiol by the hepatic cytochromes P450 CYP2C19 and CYP2C9, CYP3A4 mainly oxidising cannabidiol at other positions (Beers 2021).

Classification

Family, origin and source verification

Family

Metabolite

Parent molecule

CBD

Active metabolite.

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

7-Hydroxycannabidiol (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Beers et al. 2021, Drug Metab Dispos: CYP2C19 and CYP2C9 form 7-OH-CBD (new tab)PMID 34330718
  2. Nasrin et al. 2023, Chem Res Toxicol: inhibition of nicotine metabolism (new tab)PMID 36626330
  3. Zhang et al. 2024, Med Cannabis Cannabinoids: high-dose pharmacokinetics (new tab)PMID 38292071
  4. Wu et al. 2025, Arch Toxicol: 7-formyl-CBD intermediate (new tab)PMID 40736583
  5. Li et al. 2025, Arch Toxicol: hepatic cytotoxicity of 7-OH-CBD and 7-COOH-CBD (new tab)PMID 40029368
  6. Li et al. 2022, Food Chem Toxicol: Sertoli cells (new tab)PMID 34871667
  7. Tongkanarak et al. 2025, Int J Mol Sci: cellular metabolism and molecular docking (new tab)PMID 40943305
  8. Martin et al. 1976, J Pharm Pharmacol: monohydroxylated CBD metabolites (rat liver) (new tab)PMID 6714
  9. Nilsson et al. 1973, J Pharm Pharmacol: two CBD metabolites (rat liver) (new tab)PMID 4146589
  10. Tchilibon & Mechoulam 2000, Org Lett: first total synthesis of 7-OH-CBD (new tab)PMID 11029195
  11. Palmisani et al. 2025, Int J Mol Sci: therapeutic drug monitoring by LC-MS/MS (new tab)PMID 40725248
  12. Ujváry & Hanuš 2016, Cannabis Cannabinoid Res: human metabolites of cannabidiol (new tab)PMID 28861484
  13. FDA, Epidiolex (cannabidiol) prescribing information 2018, section 12.3 (new tab)
  14. EMA, Epidyolex EPAR: EU authorisation on 19 September 2019 (new tab)

Identifiers

Names

Common name
7-hydroxycannabidiol
IUPAC name
2-[(1R,6R)-3-(hydroxymethyl)-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Other names
7-OH-CBD · 7-hydroxy-CBD · 7-OH-cannabidiol · 7-hydroxy-cannabidiol

Identifiers

Formula
C₂₁H₃₀O₃
CAS
50725-17-2
PubChem CID
11301963(new tab)
InChIKey
ZELUXPWDPVXUEI-ZWKOTPCHSA-N
SMILES
C=1(C(=CC(=CC1O)CCCCC)O)[C@H]2[C@](CCC(=C2)CO)([H])C(C)=C

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.